Vaccines for leishmaniasis: From proteome to vaccine candidates

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 10-15

  Schroeder, Juliane ^a,c   Aebischer, Toni ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROBERT KOCH INSTITUTE   (Germany)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Proteomics; Reverse vaccinology; T cell epitopes; Vectored vaccines

Indexed keywords

HYBRID PROTEIN; LEISH F ANTIGEN; LEISH F1 ANTIGEN; LEISHMANIA VACCINE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; GENOME; HUMAN; LEISHMANIASIS; NONHUMAN; PROTEOMICS; REVIEW; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; BIOMEDICAL RESEARCH; HUMANS; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; PROTEOME;

EID: 80051671207     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14556     Document Type: Review

References (65)

1. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2:313.
2. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 2007; 1:114.
3. Singh SP, Picado A, Boelaert M, Gidwani K, Andersen EW, Ostyn B, et al. The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health 2010; 15:12-20.
4. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77. (Pubitemid 41540115)
5. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz AMd, et al. Cost-Effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 2010; 4:818.
6. Sarnoff R, Desai J, Desjeux P, Mittal A, Topno R, Siddiqui NA, et al. The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India. Trop Med Int Health 2010; 15:42-9.
7. Berberian DA. Vaccination and immunity against oriental sore. Transactions of the Royal Society of Tropical Medicine and Hygiene 1939; 33:87.
8. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 1983; 76:377-83. (Pubitemid 14229645)
9. Hosseini SM, Hatam GR, Ardehali S. Characterization of Leishmania isolated from unhealed lesions caused by leishmanization. East Mediterr Health J 2005; 11:240-3.
10. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009; 27:4747-53.
11. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 2009; 5:1000484.
12. Khamesipour A, Dowlati Y, Asilian A, Hashemi- Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005; 23:3642-8. (Pubitemid 40692409)
13. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010; 28:6581-7.
14. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M. Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int 2009; 58:319-24.
15. Kedzierski L. Leishmaniasis vaccine: Where are we today? J Glob Infect Dis 2010; 2:177-85.
16. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50. (Pubitemid 47038186)
17. Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am J Trop Med Hyg 2010; 82:808-13.
18. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997; 56:522-5. (Pubitemid 27230074)
19. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005; 309:436-42. (Pubitemid 40994677)
20. Rosenzweig D, Smith D, Opperdoes F, Stern S, Olafson RW, Zilberstein D. Retooling Leishmania metabolism: from sand fly gut to human macrophage. FASEB J 2008; 22:590-602. (Pubitemid 351225595)
21. Paape D, Lippuner C, Schmid M, Ackermann R, Barrios-Llerena ME, Zimny-Arndt U, et al. Transgenic, fluorescent Leishmania mexicana allow direct analysis of the proteome of intracellular amastigotes. Mol Cell Proteomics 2008; 7:1688-701.
22. Paape D, Barrios-Llerena ME, Le BT, Mackay L, Aebischer T. Gel free analysis of the proteome of intracellular Leishmania mexicana. Mol Biochem Parasitol 2010; 169:108-14.
23. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3:445-50.
24. Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 2009; 9:1075-82.
25. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, et al. Expression cloning of a protective Leishmania antigen. Science 1995; 268:563-6.
26. Campos-Neto A, Soong L, Cordova JL, Sant'Angelo D, Skeiky YA, Ruddle NH, et al. Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med 1995; 182:1423-33.
27. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161:6171-9. (Pubitemid 28535990)
28. Goto Y, Coler RN, Guderian J, Mohamath R, Reed SG. Cloning, characterization and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun 2006; 74:3939-45. (Pubitemid 43993326)
29. Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995; 181:1527-37.
30. Probst P, Stromberg E, Ghalib HW, Mozel M, Badaro R, Reed SG, et al. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 2001; 166:498-505. (Pubitemid 32038469)
31. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007; 75:4648-54. (Pubitemid 47378126)
32. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, Coler RN, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010; 28:7427-35.
33. Goto Y, Coler RN, Reed SG. Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun 2007; 75:846-51. (Pubitemid 46203448)
34. Aebischer T, Wolfram M, Patzer SI, Ilg T, Wiese M, Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68:1328-36. (Pubitemid 30108529)
35. Wolfram M, Fuchs M, Wiese M, Stierhof YD, Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Eur J Immunol 1996; 26:3153-62. (Pubitemid 26411526)
36. Prickett S, Gray PM, Colpitts SL, Scott P, Kaye PM, Smith DF. In vivo recognition of ovalbumin expressed by transgenic Leishmania is determined by its subcellular localization. J Immunol 2006; 176:4826-33.
37. Overath Pand Aebischer T. Antigen presentation by macrophages harboring intravesicular pathogens. Parasitol Today 1999; 15:325-32.
38. Horn D. Codon usage suggests that translational selection has a major impact on protein expression in trypanosomatids. BMC Genomics 2008; 9:2.
39. Holzer TR, McMaster WR, Forney JD. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes and axenic amastigotes in Leishmania mexicana. Mol Biochem Parasitol 2006; 146:198-218. (Pubitemid 43356361)
40. Leifso K, Cohen-Freue G, Dogra N, Murray A, McMaster WR. Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed. Mol Biochem Parasitol 2007; 152:35-46. (Pubitemid 46107698)
41. + T cells requires the presence of cognate antigen. Infect Immun 2006; 74:773-6.
42. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003; 9:1287-92. (Pubitemid 37279852)
43. + cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun 2007; 75:5956-66.
44. Mary C, Auriault V, Faugere B, Dessein AJ. Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells. Infect Immun 1999; 67:5559-66. (Pubitemid 29508070)
45. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC. Bioinformatics 2008; 9:22.
46. Buus S, Lauemoller SL, Worning P, Kesmir C, Frimurer T, Corbet S, et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003; 62:378-84. (Pubitemid 37345160)
47. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003; 12:1007-17. (Pubitemid 36505435)
48. Italian Genome Variation Consortium. The Indian Genome Variation database (IGVdb): a project overview. Hum Genet 2005; 118:1-11.
49. Mehra NK, Jaini R, Rajalingam R, Balamurugan A, Kaur G. Molecular diversity of HLA-A*02 in Asian Indians: predominance of A*0211. Tissue Antigens 2001; 57:502-7. (Pubitemid 32783721)
50. Basu R, Roy S, Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 2007; 195:1373-80. (Pubitemid 46649626)
51. Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001; 19:3169-78. (Pubitemid 32324046)
52. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, Sack F, Moreno S, Konig SA, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21:247-57. (Pubitemid 35346820)
53. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9:1899-907. (Pubitemid 28439095)
54. Almeida R, Norrish A, Levick M, Vetrie D, Freeman T, Vilo J, et al. From genomes to vaccines: Leishmania as a model. Philos Trans R Soc Lond B Biol Sci 2002; 357:5-11. (Pubitemid 34147258)
55. Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, Almeida R, et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006; 24:2602-16. (Pubitemid 43290392)
56. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice. Infect Immun 2007; 75:852-60. (Pubitemid 46203449)
57. Perez-Jimenez E, Kochan G, Gherardi MM, Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect 2006; 8:810-22.
58. Gabaglia CR, Pedersen B, Hitt M, Burdin N, Sercarz EE, Graham FL, et al. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice. J Immunol 1999; 162:753-60. (Pubitemid 29035396)
59. Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA-Salmonella enterica serovar Typhimurium primerbooster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004; 72:4924-8. (Pubitemid 38989360)
60. McSorley SJ, Xu D, Liew FY. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun 1997; 65:171-8. (Pubitemid 27008919)
61. Xu D, McSorley SJ, Chatfield SN, Dougan G, Liew FY. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA-AroD-). Immunology 1995; 85:1-7.
62. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145:2281-5. (Pubitemid 20343397)
63. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78-83.
64. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, Mahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 2005; 73:5286-9. (Pubitemid 41105698)
65. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008; 26:333-44.